Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Lotus Pharmaceuticals, Inc. (OTC: LTUS).

Full DD Report for LTUS

You must become a subscriber to view this report.

Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LTUS.

About Lotus Pharmaceuticals, Inc. (OTC: LTUS)

Logo for Lotus Pharmaceuticals, Inc. (OTC: LTUS)

Lotus Pharmaceuticals is both a licensed manufacturer and distributor of pharmaceutical products in the People s Republic of China. Its principal manufactured products are prescription medicines, including Valsartan, used to reduce hypertension and high blood pressure Brimonidine Tartrate, a glaucoma treatment Levofloxacin Lactate, an intravenous anti bacterial and Nicergoline, an anti dementia drug. The company also distributes products on behalf of third party pharmaceutical manufacturers directly through its distribution network.


Contact Information



Current Management

  • Dr.Zong Yi Liu / CEO
  • Yan Zeng / CFO
  • Dr.Zong Yi Liu / Chairman

Current Share Structure

  • Market Cap: $417,247 - 03/16/2018
  • Issue and Outstanding: 27,816,455 - 11/10/2011


Daily Technical Chart for (OTC: LTUS)

Daily Technical Chart for (OTC: LTUS)

Stay tuned for daily updates and more on (OTC: LTUS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: LTUS)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LTUS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of LTUS and does not buy, sell, or trade any shares of LTUS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: